GLAXO · Healthcare · Drug Manufacturers - General
Composite scorecard: 59/100 — Quality 100 · Valuation 35 · Growth 56 · Momentum 8
| Share price | ₹2,483.10 |
| Market cap | ₹43,564 Cr |
| P/E ratio | 42.7 |
| P/B ratio | 25.5 |
| ROE | 75.5% |
| ROCE | 57.3% |
| Dividend yield | 1.63% |
| Book value | ₹100.81 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹3,822 Cr | ₹1,036 Cr | 34.0% |
| 2025 | ₹3,749 Cr | ₹928 Cr | 31.0% |
| 2024 | ₹3,454 Cr | ₹590 Cr | 26.0% |
| 2023 | ₹3,252 Cr | ₹611 Cr | 25.0% |
| 2022 | ₹3,278 Cr | ₹1,695 Cr | 23.0% |
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tet